MET Registry

Author:  Julia Dobke, Last modification: 2024/07/03 https://kinderkrebsinfo.de/doi/e246079

MET Registry

Prospective, multicenter registry for the detection of malignant endocrine tumours in children and adolescents
Disease 1. Thyroid carcinoma (TC): differentiated thyroid carcinoma (DTC), medullary thyroid carcinoma (MTC), C-cell hyperplasia (CCH) with pathogenic variant in the RET proto-oncogene, other thyroid carcinomas 2. Adrenocortical tumour (ACT): adrenocortical carcinoma (ACC), adrenocortical adenoma (ACA), adrenocortical tumour of unclear dignity (ACx) 3. Phaeochromocytoma (PCC) and paraganglioma (PGL) 4. Gastroenteropancreatic neuroendocrine neoplasia (GEP-NEN): neuroendocrine tumour (NET) and carcinoma (NEC) of appendix, bronchus, pancreas and other locations.
Type

Prospective, multicenter registry
Rationale / Objectives
  • The prospective recording of all children and adolescents with a first diagnosis of a malignant endocrine tumour from the age of 0 to the age of 18
  • Scientific evaluation with the aim of optimising therapy for patients
Therapy / Study arms

Recommendations on the diagnostic procedures, therapy and aftercare of malignant endocrine tumours in children and adolescents are not part of the new MET registry (protocol). The responsible physicians are provided with published national recommendations on diagnostics and treatments for the entities recorded in the MET Registry (ACT, DTC, MTC, NET, PPGL) based on the current scientific knowledge and current evaluations of the MET Registry, which are not part of the registry protocol.
A European recommendation already exists for the entity of the ACT (Virgone, C., et al., Pediatr Blood Cancer, 2021).

If necessary, a patient-specific consultation request can be made to the MET Help Desk. For this purpose, a corresponding informed consent must be obtained by the treating clinic from the respective patient (16 years of age or older) and/or their legal guardian.
Inclusion Criteria
  • Patients aged 0 to 18 years
  • Diagnosis of a malignant endocrine tumour
Status Start: 14.04.2022 until further notice
Principal Investigator Dr. med. Antje Redlich
E-Mail met@med.ovgu.de
URL https://kpae.med.ovgu.de/Forschung/MET+Register.html
Contact

Principal investigator

Dr. med. Antje Redlich Universitätsklinikum Magdeburg A.ö.R. Universitätskinderklinik, Leiterin Bereich Pädiatrische Hämatologie und Onkologie Leipziger Str. 44 39120 Magdeburg Telefon +49 391 67 24240 Fax +49 (391) 672 90044 antje.redlich@med.ovgu.de

Deputy

PD Dr. med. Michaela Kuhlen Universitätsklinikum Augsburg Schwäbisches Kinderkrebszentrum Klinik für Kinder und Jugendliche Stenglinstr. 2 86156 Augsburg Telefon + 49 821 400 169307 Fax +49 821 400 179307 michaela.kuhlen@uk-augsburg.de

Medical coordinator

Dr. med. Marina Kunstreich Universitätsklinikum Magdeburg A.ö.R. Pädiatrische Hämatologie und Onkologie Leipziger Str. 44 39120 Magdeburg Telefon +49 391 67 24240 Fax +49 391 67 290044 marina.kunstreich@med.uvgu.de

Dr. med. Marie Wölfer Universitätsklinikum Magdeburg A.ö.R. Pädiatrische Hämatologie und Onkologie Leipziger Str. 44 39120 Magdeburg Telefon +49 391 67 24240 Fax +49 391 67 290044

Documentation

Nadine Ringleb Universitätsklinikum Magdeburg A.ö.R. Universitätskinderklinik, Pädiatrische Hämatologie und Onkologie Leipziger Straße 44 39120 Magdeburg Telefon +49 (391) 6724244 Fax +49 (391) 67290044 met@med.ovgu.de

Birka Koppe Universitätsklinikum Magdeburg A.ö.R. Pädiatrische Hämatologie und Onkologie Leipziger Str. 44 39120 Magdeburg Telefon +49 391 67 24240 Fax +49 391 67 290044 met@med.ovgu.de

Participants Deutsche GPOH-Kliniken
Documents
Sponsoring Deutsche Kinderkrebsstiftung